Disease Management Comes of Age, Not a Moment too Soon

A closer look at the available PrEP options available in the United States.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

The regimen has shown promise in preventing graft-versus-host disease in patients who received a haploidentical stem cell transplant.

Hympavzi is the first anti-tissue factor pathway inhibitor approved in the United States for hemophilia.